ClinicalTrials.gg
Active, not recruitingNCT06523530EndomMASLDUpdated Jul 23, 2026

Effect of a GnRH Analog on Hepatic Steatosis

A Phase 4 interventional study of Goserelin Acetate 3.6 mg inj, implant in Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver and Endometriosis, sponsored by Aristotle University Of Thessaloniki. Active, not recruiting at 2 sites in Greece. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece — 3 open to participants now, 6 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Greece.

Planned enrollment
14th of 20
62 · median 100
Started
2024
with 1 other
Phase 4
2 of 24
none open now
Registered
23rd of 24
by date
Lead sponsor
3 of 24
Aristotle University Of Thessaloniki

Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 23rd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

3 of the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, or all of them as a file.
02

Study summary

Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.

Read the detailed description

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), which until recently was known as nonalcoholic fatty liver disease (NAFLD), has risen to 30% of the global adult general population, whereas the pharmaceutical interventions against it remain limited. Owing to the epidemiologic and pathophysiologic association of MASLD with obesity, type 2 diabetes mellitus, dyslipidemia and arterial hypertension, the diagnostic criteria for MASLD are similar to those of the metabolic syndrome.

Menopause has been associated with higher MASLD prevalence, with the lack of estrogen being a very plausible pathogenetic contributor to this liver disease. Other pathogenetic contributors of MASLD, including abdominal obesity, increase in insulin resistance (IR) and dysmetabolism of carbohydrates and lipids, are aggravated after menopause, thus adversely contributing to the pathogenesis of MASLD. Regarding the effect of the lack of estrogen on the liver, most to date data are derived from experimental studies, largely showing a favoring effect on MASLD. Epidemiological studies have also shown menopause as an associate of MASLD. However, existing clinical studies are mostly observational, thereby not being able to show a causative association between menopause and MASLD.

Gonadotropin-releasing hormone (GnRH) treatment in disorders such as endometriosis can be regarded as a model of pharmaceutical menopause. More specifically, GnRH analogs, like goserelin acetate, lead to pharmaceutical menopause by suppressing the axis hypothalamus-pituitary-ovaries, thus, causing an iatrogenic, reversible ovarian cessation, which lasts as long as the use of GnRH. The adverse effects of GnRH are generally mild and reversible after their discontinuation.

This is a prospective, interventional non-randomized study, which aims to evaluate the effect of goserelin acetate on hepatic steatosis in women with histologically confirmed endometriosis compared with women with endometriosis that will not receive pharmacological treatment post-surgically.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Nonalcoholic Fatty Liver
  • Endometriosis

Keywords

  • endometriosis
  • goserelin acetate
  • hepatic fibrosis
  • MASLD
  • MASH
  • metabolic dysfunction-associated steatotic liver disease
  • metabolic dysfunction-associated steatohepatitis
  • NAFLD
  • NASH
  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • treatment
  • menopause
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women of reproductive age
  • diagnosis of endometriosis. The disease is suspected by patient's individual history (chronic pelvic pain, dyspareunia or/and dysmenorrhea) and the ultrasonographic imaging (chocolate cysts). The diagnosis is confirmed histologically, after laparoscopic surgical treatment and sampling, which will be interpreted by an independent blinded pathologist.
  • use of , which is the treatment, is or the patient does not consent to receive contraceptives, due to personal preferences.
  • written to participate to the study

Exclusion criteria

Exclusion Criteria:

  • mean ethanol consumption >10 g/day
  • history of other chronic liver disease (e.g., viral hepatitis, hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)
  • liver cirrhosis
  • any
  • chronic kidney disease
  • uncontrolled hypothyroidism or hyperthyroidism
  • severe sexual hormone disorders (congenital adrenaline hyperplasia, Down syndrome, Turner syndrome).
  • use of the following medications within a 12-month period before baseline, which are associated with drug-induced liver injury (DILI): interferon, tamoxifen, amiodarone, aloperidin, , hormone replacement therapy, , anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition
  • use of the following medications within a 12-month period before baseline, which are probably associated with improvement in hepatic steatosis: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium- glucose co-transporter-2 inhibitors (SGLT-2i), orlistat, ursodeoxycholic acid
  • use of any GnRH agonist or antagonist within a 12-month period before baseline
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Goserelin

    31 women with histologically confirmed endometriosis will receive goserelin acetate post-surgically.

    Drug: Goserelin Acetate 3.6 mg inj, implant

  • No intervention
    Control

    31 women with histologically confirmed endometriosis will not receive pharmacological treatment post-surgically.

Interventions

  • DrugGoserelinStudies of GoserelinGoserelin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)

    Also known as: Zoladex

06

What researchers measure

Primary outcomes

  1. Hepatic steatosis

    Ultrasound-Guided Attenuation Parameter (UGAP) measured on an ultrasound machine GE Logiq E10s. Between-within group interactions in UGAP UGAP is a non-invasive index based on the attenuation quantification of the ultrasound beam through the hepatic parenchyma, thus used for hepatic steatosis quantification. Cut-off values of ≥ 0.53 dB/cm/MHz, ≥ 0.60 dB/cm/MHz, and ≥ 0.65 dB/cm/MHz have been proposed for the diagnosis of steatosis grade S1, S2, and S3, respectively

    Time frame: 6 months

  2. Hepatic fibrosis

    Liver stiffness (LS) measured with 2D Shear Wave Elastography (2D SWE) on an ultrasound machine GE Logiq E10s. Between-within group interactions in LS 2D SWE is a non-invasive tool measuring the hepatic parenchyma stiffness, thus indirectly suggesting fibrosis stage (F). Cut-offs values of \<8.27 kPa, 8.27-9.39 kPa, 9.40-11.88 kPa and ≥11.88 kPa have been proposed for F0-F1, F2, F3, and F4, respectively.

    Time frame: 6 months

Secondary outcomes

  1. Liver function tests I - ALT and AST

    Between-within group interactions will be performed for each of the following parameters: Alanine aminotransferase (ALT; IU/l), aspartate aminotransferase (AST; IU/l); ALT to AST ratio will be calculated

    Time frame: 6 months

  2. Liver function tests II - γGT

    Between-within group interactions will be performed for: γ-glutamyltransferase (GGT; IU/l)

    Time frame: 6 months

  3. Insulin resistance

    Between-within group interactions will be performed for Homeostasis Model Assessment - Insulin Resistance (HOMA-IR), which is calculated by the formula: fasting glucose (mg/dl) × insulin (mU/l)/405, and is an index of insulin resistance; higher score indicates greater insulin resistance.

    Time frame: 6 months

  4. Lipid profile

    Between-within group interactions will be performed for each of the following parameters: Total cholesterol (TC; mg/dL) Triglycerides (TG; mg/dL) High-density lipoprotein cholesterol (HDL-C; mg/dL) 4. Low-density lipoprotein cholesterol (LDL-C) LDL-C (mg/dL) is calculated by the formula: TC (mg/dl) - HDL-C (mg/dl) - TG (mg/dl)/5.

    Time frame: 6 months

  5. Non-invasive hepatic steatosis index I - Fatty Liver Index (FLI)

    FLI is calculated by the formula \[(e0.953 × Loge (TG, mg/dL) + 0.139×BMI (kg/m2) + 0.718× Loge (GGT, U/L) + 0.053 × waist circumference (cm) -15.745) / (1 + e0.953 × Loge (TG, mg/dL) + 0.139×BMI (kg/m2) + 0.718×Loge (GGT, U/L) + 0.053 × waist circumference (cm) -15.745)\] × 100. Between-within group interactions will be performed.

    Time frame: 6 months

  6. Non-invasive hepatic steatosis index II - Hepatic Steatosis Index (HSI)

    HSI is calculated by the formula: 8 \* ALT (U/L) / AST (U/L) + BMI (kg/m2) + 2 \[if type 2 diabetes melitus (T2DM)\] + 2 (if female). Between-within group interactions will be performed.

    Time frame: 6 months

  7. Non-invasive hepatic steatosis index III - Triglyceride/Glucose Index (TyG)

    TyG is calculated by the formula: Ln\[TG (mg/dL) \* Glu (mg/dL) / 2\]. Between-within group interactions will be performed.

    Time frame: 6 months

  8. Non-invasive hepatic steatosis index IV - Tyg-BMI

    Tyg-BMI is calculated by the formula: TyG \* BMI (kg/m2). Between-within group interactions will be performed.

    Time frame: 6 months

  9. Non-invasive hepatic steatosis indices V - NAFLD test

    NAFLD test is calculated by the formula: -0.695 + 0.031 \* BMI (kg/m2) + 0.003 \* TC (mg/dL) + 0.014 \* ALT (U/L) + 0.025 \* C-reactive protein (CRP) (mg/dL). Between-within group interactions will be performed.

    Time frame: 6 months

  10. Non-invasive hepatic steatosis index VI - Metabolic Score for Insulin Resistance (MetS-IR)

    MetS-IR is calculated by the formula: Ln\[2 \* Glu (mg/dL) + TG (mg/dL)\] \* BMI (kg/m2) / Ln\[HDL-C (mg/dL)\]. Between-within group interactions will be performed.

    Time frame: 6 months

  11. Non-invasive hepatic steatosis index VII - Lipid Accumulation Product index (LAP)

    LAP is calculated by the formula: \[WC (cm) - 58\] \* \[TG (mg/dL) / 88.57\]. Between-within group interactions will be performed.

    Time frame: 6 months

  12. Non-invasive hepatic steatosis index VIII - Liver Fat Score (LFS)

    LFS is calculated by the formula: -2.89 + 1.18 (if metabolic syndrome) + 0.45 \* 2 (if T2DM) + 0.15 \* insulin (mU/L) + 0.04 \* AST (U/L) - 0.94 \* AST (U/L) / ALT (U/L). Between-within group interactions will be performed.

    Time frame: 6 months

  13. Non-invasive hepatic fibrosis index I - NAFLD fibrosis score (NFS)

    NFS is calculated by the formula: -1.675 + 0.037 \* age (years) + 0.094 \* BMI (kg/m2) + 1.13 (if impaired fasting glucose or T2DM) + 0.99 \* AST (U/L) / ALT (U/L) - 0.013 \* platelet count \[\*10(9)/L\] - 0.66 \* albumin (g/dL). Between-within group interactions will be performed.

    Time frame: 6 months

  14. Non-invasive hepatic fibrosis index II - Fibrosis-4 index (FIB-4)

    FIB-4 is calculated by the formula: age (years) \* AST (U/L) / {platelet count \[\*10(9)/L\] \* √ALT (U/L)}. Between-within group interactions will be performed.

    Time frame: 6 months

  15. Non-invasive hepatic fibrosis index III - AST-to-Platelet Ratio Index (APRI)

    APRI is calculated by the formula: AST (U/L) / upper limit of normal \* 100 / platelet count \[\*10(9)/L\]. Between-within group interactions will be performed.

    Time frame: 6 months

  16. Non-invasive hepatic fibrosis index IV - Metabolic dysfunction-Associated Fibrosis Score (MAF-5)

    MAF-5 is calculated by the formula: -11.3674 + 0.0282 \* WC (cm) - 0.1761 \* BMI (kg/m2) + 0.0019 \* WC (cm) \* BMI (kg/m2) + 2.0762 (if T2DM) + 2.9207 \* Ln\[AST (U/L)\] - 0.0059 \* platelet count \[\*10(9)/L\]. Between-within group interactions will be performed.

    Time frame: 6 months

  17. Adiponectin

    Adiponectin is measured in μg/mL. Between-within group interactions will be performed.

    Time frame: 6 months

  18. Leptin

    Leptin is measured in ng/mL. Between-within group interactions will be performed.

    Time frame: 6 months

  19. Tumor Necrosis Factor-α (TNF-α)

    TNF-a is measured in pg/mL. Between-within group interactions will be performed.

    Time frame: 6 months

  20. Sex hormones I - Estradiol

    Estradiol is measured in pg/mL. Between-within group interactions will be performed.

    Time frame: 6 months

  21. Sex hormones II - Testosterone

    Testosterone is measured in ng/mL. Between-within group interactions will be performed.

    Time frame: 6 months

  22. Sex hormones III - Sex Hormone Binding Globulin (SHBG)

    SHBG is measured in nmol/L. Between-within group interactions will be performed.

    Time frame: 6 months

07

Study locations

2 sites
  • 424 General Military Hospital
    Thessaloniki, Thessaloniki 56429, Greece
  • 1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki
    Thessaloniki, 56403, Greece
08

References and documents

Publications

  • Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022 Sep;56(6):942-956. doi: 10.1111/apt.17158. Epub 2022 Jul 26. PubMed 35880713 ↗
  • Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gomez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. PubMed 37363821 ↗
  • Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May;23(5):469-80. doi: 10.1111/j.1464-5491.2006.01858.x. PubMed 16681555 ↗
  • Polyzos SA, Lambrinoudaki I, Goulis DG. Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. Hormones (Athens). 2022 Sep;21(3):375-381. doi: 10.1007/s42000-022-00369-8. Epub 2022 May 9. PubMed 35532850 ↗
  • Polyzos SA, Goulis DG. Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas. 2024 Aug;186:108024. doi: 10.1016/j.maturitas.2024.108024. Epub 2024 May 14. PubMed 38760254 ↗
  • Palmisano BT, Zhu L, Stafford JM. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv Exp Med Biol. 2017;1043:227-256. doi: 10.1007/978-3-319-70178-3_12. PubMed 29224098 ↗
  • Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 2019;17(6):546-555. doi: 10.2174/1570161116666180711121949. PubMed 29992886 ↗
  • Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016 Sep;42(9):1152-8. doi: 10.1111/jog.13023. Epub 2016 May 26. PubMed 27225336 ↗
  • Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018 Jul;19(10):1109-1125. doi: 10.1080/14656566.2018.1494154. Epub 2018 Jul 5. PubMed 29975553 ↗
  • DiVasta AD, Laufer MR. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Curr Opin Obstet Gynecol. 2013 Aug;25(4):287-92. doi: 10.1097/GCO.0b013e32836343eb. PubMed 23770813 ↗
  • Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020 Oct;111S:154203. doi: 10.1016/j.metabol.2020.154203. Epub 2020 Mar 6. PubMed 32151660 ↗
  • Polyzos SA, Kountouras J, Tsatsoulis A, Zafeiriadou E, Katsiki E, Patsiaoura K, Zavos C, Anastasiadou VV, Slavakis A. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones (Athens). 2013 Jul-Sep;12(3):405-16. doi: 10.1007/BF03401306. PubMed 24121382 ↗
  • Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest. 2022 Sep;45(9):1609-1623. doi: 10.1007/s40618-022-01766-x. Epub 2022 Mar 18. PubMed 35303270 ↗

Individual participant data

Plan to share: Yes — IPD will be available to other researchers upon reasonable request

Supporting information: Study protocol, Statistical analysis plan

Time frame: 12 months after the publication of the study.

Access criteria: Yet unknown

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 41 non-industry phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 29 months is above that.

Counting every sponsor, half of 44 studies reached it within 25 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 26, 2024
StartActual
Nov 26, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06523530
Collaborators
424 General Military Hospital
Responsible party
Stergios A Polyzos (Associate Professor of Pharmacology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Jul 26, 2024
Start date
Nov 26, 2024
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Dimitrios A Anastasilakis, MD, PhDc
study director · School of Medicine, Aristotle University of Thessaloniki
Athina I Gkiomisi, MD, PhD
study director · 424 General Military Hospital, Thessaloniki, Greece
Dimitrios G Goulis, MD, PhD
study director · School of Medicine, Aristotle University of Thessaloniki
Angelos Daniilidis, MD, PhD
study director · School of Medicine, Aristotle University of Thessaloniki
Athanasios A Anastasilakis, MD, PhD
study director · 424 General Military Hospital, Thessaloniki, Greece
Chrysi Nalmpantidou, MD
study director · "G. Gennimatas" General Hospital, Thessaloniki, Greece
Stergios A Polyzos, MD, PhD
principal investigator · School of Medicine, Aristotle University of Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion